Genfit (GNFT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec10

Genfit SA reports preliminary results of GNS561 and MEK inhibitor combination for KRAS-mutated cholangiocarcinoma Phase 1b trial

17:00

Nov10

GENFIT Partners with EVerZom to Enhance ACLF Research Using Exosome-based Regenerative Technology

07:07

Genfit SA presents preclinical data of G1090N for ACLF treatment

06:30

Sep23

Genfit released FY2025 Semi-Annual earnings on September 22 (EST), actual revenue USD 40.18 M (forecast USD 115.36 M), actual EPS USD -0.2253 (forecast USD -0.1521)

03:00

Genfit released FY2025 Q1 earnings on September 22 (EST), actual revenue USD 19.23 M (forecast USD 143.75 M), actual EPS USD -0.1082

03:00

Genfit released FY2025 Q2 earnings on September 22 (EST), actual revenue USD 20.8 M (forecast USD 33.61 M), actual EPS USD -0.117

03:00

Schedules & Filings

Schedules

Filings

Nov20

Ticker Change(EST)

From 11.20 changed to GNFTY

Sep22

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 20.8 M, Net Income -5.827 M, EPS -0.117

Apr24

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 4.988 M, Net Income -14.98 M, EPS -0.3183

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More